Evidence supports the concept that therapeutic reduction of intra-arterial pressure (blood pressure) well into the biologically normal range confers substantial protection against death and target organ damage associated with arterial hypertension. This is especially true for patients who also have diabetes mellitus, chronic renal disease, isolated systolic hypertension, or other cardiovascular risk factors. There is also evidence that most patients will require more than one drug in order to achieve these more aggressive therapeutic goals. Therefore, it has become appropriate to use more than one drug as initial therapy for such patients (1). Many commercially available combination products are now recommended for initial antihypertensive therapy.
|Original language||English (US)|
|Title of host publication||Hypertension|
|Subtitle of host publication||Principles and Practice|
|Number of pages||14|
|ISBN (Print)||0824728556, 9780824728557|
|State||Published - Jan 1 2005|
ASJC Scopus subject areas